Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

everolimus

- PMLiVE

Novartis claims EU approval for breast cancer drug Kisqali

Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe

- PMLiVE

Novartis appoints Shaun Coughlin to lead its US biomedical research institute

The renowned academic joins as the pharma firm's global head of cardiovascular and metabolism

- PMLiVE

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

Bristol-Myers Squibb (BMS) building

BMS data add to checkpoint inhibitor combo confusion

Opdivo and Yervoy meet one objective but miss another in CheckMate-214

- PMLiVE

NICE expands Merck KGaA’s Erbitux reach

Backs the medicines use for patients with SCCHN

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

NICE backs Cancer Drugs Fund support for Roche’s Gazyvaro

Lymphoma treatment will be used in conjunction with chemotherapy

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

NICE backs Teva’s Cinqaero for severe asthma

Ruling will allow it to compete with GSK's rival IL-5 inhibitor Nucala

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links